ELA026
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Key Facts
About Electra Therapeutics
Electra Therapeutics is a private, clinical-stage biotech focused on developing novel SIRP-targeted antibodies with a unique mechanism of action for immunology and oncology. The company's lead asset, ELA026, is advancing in a pivotal Phase 2/3 trial for the life-threatening hyperinflammatory disease sHLH, with expansion into hematologic cancers planned. A second program, ELA822, is being advanced toward the clinic for immunology and inflammation. With a presentation scheduled at a major healthcare conference, the company is actively seeking visibility as it progresses its pipeline.
View full company profileAbout Electra Therapeutics
Electra Therapeutics is a private, clinical-stage biotech focused on developing novel SIRP-targeted antibodies with a unique mechanism of action for immunology and oncology. The company's lead asset, ELA026, is advancing in a pivotal Phase 2/3 trial for the life-threatening hyperinflammatory disease sHLH, with expansion into hematologic cancers planned. A second program, ELA822, is being advanced toward the clinic for immunology and inflammation. With a presentation scheduled at a major healthcare conference, the company is actively seeking visibility as it progresses its pipeline.
View full company profile